Article
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2018
Soo Ross A, Lim Sun Min, Syn Nicholas L, Teng Rebecca, Soong Richie, Mok Tony S K, Cho Byoung Chul
Abstract excerpt
Major advances with the development of epidermal growth factor receptor tyrosine kinase inhibitors and immune check-point inhibitors have ushered in a new era in lung cancer therapy. Whilst pre-clinical studies suggest EGFR-driven NSCLC inhibit antitumor immunity through the activation of the PD-1/PD-L1 pathway, epidemiology studies suggest EGFR mutant NSCLC are more likely to have decreased PD-L1 expression. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.